9-甲基咔唑-3-胺 | 61166-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 9-甲基咔唑-3-胺
• 英文名称: 3-amino-N-methylcarbazole
• 英文别名: 3-amino-9-methylcarbazole；9-methyl-9H-carbazol-3-amine；9-methyl-3-aminocarbazole；9-methyl-9H-carbazole-3-amine；3-amino-9-methyl-9H-carbazole；9-methylcarbazol-3-amine
• CAS: 61166-04-9
• 化学式: C₁₃H₁₂N₂
• mdl: MFCD01752023
• 分子量: 196.252
• InChiKey: AIMXMLCYGWOKDI-UHFFFAOYSA-N

物化性质

• 熔点：
  174 °C
• 沸点：
  415.4±27.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 储存条件：
  存储温度应保持在2-8°C，并避免光照。

反应信息

• 作为反应物：
  描述：

  9-甲基咔唑-3-胺 在 镍 吡啶 、 sodium hydroxide 、 氢气 、 硝酸 、 溶剂黄146 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 18.0h， 生成 9-methyl-3,4-diaminocarbazole
  参考文献：
  名称：

  Agarwal, Alka; Agarwal, Shiv K; Bhakuni, D S, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1992, vol. 31, # 1, p. 44 - 49

  摘要：

  DOI：
• 作为产物：
  描述：

  在 copper(I) chloride bis(lithium chloride) complex 、 3,3’-di-tert-butyl oxaziridine 作用下， 以 四氢呋喃 为溶剂， 反应 0.67h， 以61%的产率得到9-甲基咔唑-3-胺
  参考文献：
  名称：

  Non-Deprotonative Primary and Secondary Amination of (Hetero)Arylmetals

  摘要：

  Herein we disclose a novel method for the facile transfer of primary (-NH2) and secondary amino groups (-NHR) to heteroaryl- as well as arylcuprates at low temperature without the need for precious metal catalysts, ligands, excess reagents, protecting and/or directing groups. This one-pot transformation allows unprecedented functional group tolerance and it is well suited for the amination of electron-rich, electron-deficient as well as structurally complex (hetero)arylmetals. In some of the cases, only catalytic amounts of a copper(I) salt is required.

  DOI：

  10.1021/jacs.6b12712

文献信息

• Design, synthesis and biological evaluation of LX2343 derivatives as neuroprotective agents for the treatment of Alzheimer's disease
  作者：Guanglong Sun、Junwei Wang、Xiaodan Guo、Min Lei、Yinan Zhang、Xiachang Wang、Xu Shen、Lihong Hu

  DOI：10.1016/j.ejmech.2017.12.080

  日期：2018.2

  A series of LX2343 derivatives were designed, synthesized and evaluated as neuroprotective agents for Alzheimer's disease (AD) in vitro. Most of the compounds displayed potent neuroprotective activities. Especially for compound A6, exhibited a remarkable EC50 value of 0.22 μM. Further investigation demonstrated that compound A6 can significantly reduce Aβ production and increase Aβ clearance, and alleviate

  设计，合成和评估了一系列LX2343衍生物作为体外阿尔茨海默氏病（AD）的神经保护剂。大多数化合物显示出有效的神经保护活性。特别是对于化合物A6，其EC 50值显着为0.22μM。进一步的研究表明，化合物A6可以显着降低Aβ的产生并增加Aβ的清除，并减轻Tau的过度磷酸化。最重要的是，化合物A6可以改善APP / PS1转基因小鼠的学习和记忆障碍。本研究显然表明化合物A6 是有效的神经保护剂，可以作为治疗阿尔茨海默氏病的有希望的主要候选药物。
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC) 충남대학교산학협력단(220040084104) BRN ▼314-82-09264

  公开号：KR20160108281A

  公开（公告）日：2016-09-19

  본 발명은 강심 활성을 지니는 화합물 및 이를 함유하는 약학적 조성물을 개시하며, 본 발명에 따른 화합물을 포함하는 조성물은 심부전의 예방 및 치료에 유용하다.

  本发明揭示了具有强心活性的化合物及含有该化合物的药学组合物，根据本发明含有该化合物的组合物对预防和治疗心力衰竭是有益的。
• 3-Aminocarbazole Compounds, Pharmaceutical Composition Containing the Same and Method for the Preparation Thereof
  申请人：Alisi Maria Alessandra

  公开号：US20080207727A1

  公开（公告）日：2008-08-28

  A compound of formula (I), in which R1, R2, R3, R4, R5, R6, X and Y have the meanings indicated in the description, and the pharmaceutically acceptable salts thereof. A pharmaceutical composition containing a compound of formula (I) or a pharmaceutically acceptable salt thereof. A method for preparing the abovementioned compound of formula (I) and the pharmaceutically acceptable salts thereof.

  公式（I）的化合物，其中R1、R2、R3、R4、R5、R6、X和Y具有描述中指示的含义，以及其药学上可接受的盐。含有公式（I）的化合物或其药学上可接受的盐的药物组合物。制备上述公式（I）化合物及其药学上可接受的盐的方法。